Literature DB >> 26513123

HIV serostatus disclosure: development and validation of indicators considering target and modality. Results from a community-based research in 5 countries.

Marie Préau1, Dominic Beaulieu-Prévost2, Emilie Henry3, Adeline Bernier4, Ludivine Veillette-Bourbeau5, Joanne Otis5.   

Abstract

RATIONALE: HIV serostatus disclosure is a complex challenge for persons living with HIV (PLHIV). Despite its beneficial effects, it can also lead to stigmatization and rejection. The current lack of multi-dimensional measurement tools impede an in-depth understanding of the dynamic of disclosure.
OBJECTIVE: To develop and validate complex measures of serostatus disclosure.
METHODS: This international community based research study was performed by joint research teams (researchers/community based organizations (CBO)) in five countries (Democratic Republic of the Congo, Ecuador, Mali, Morocco and Romania). A convenience sample of 1500 people living with HIV (PLHIV) in contact with local CBO were recruited in 2011 (300 in each country). Face-to-face interviews were performed using a 125-item questionnaire covering HIV status disclosure to 23 potential disclosure targets and related issues (including personal history with HIV, people's reaction to disclosure, sexuality). A principal component analysis and a hierarchical cluster analysis were performed, in order to identify the main components of HIV disclosure, create measures and classify participants into profiles.
RESULTS: Patterns of disclosure were summarized using two main measures: direct and indirect disclosure. Disclosure to sexual partners, whether steady or not, was different from patterns of disclosure to other targets. Among the participants, three profiles emerged - labelled Restricted disclosure, Mainly indirect disclosure and Mainly direct disclosure, respectively representing 61%, 13% and 26% of the total sample. The profiles were associated with different aspects of PLHIV's lives, including self-efficacy, functional limitations and social exclusion. Patterns varied across the five studied countries.
CONCLUSION: Results suggest that multi-dimensional constructs should be used to measure disclosure in order to improve understanding of the disclosure process.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Community-based-research; Cultural contexts; Disclosure modalities; Disclosure process; HIV infection

Mesh:

Year:  2015        PMID: 26513123     DOI: 10.1016/j.socscimed.2015.10.034

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  5 in total

Review 1.  HIV Disclosure Anxiety: A Systematic Review and Theoretical Synthesis.

Authors:  Michael Evangeli; Abigail L Wroe
Journal:  AIDS Behav       Date:  2017-01

2.  'We're touching the topic, but we're not opening the book:' A grounded theory study of sibling relationships in young people with perinatally acquired HIV.

Authors:  Hannah Deakin; Graham Frize; Caroline Foster; Michael Evangeli
Journal:  J Health Psychol       Date:  2020-10-13

3.  Predictors Associated With HIV Status Non-Disclosure in Korea.

Authors:  Kyungmin Kim; Jungmin Woo
Journal:  J Korean Med Sci       Date:  2022-04-25       Impact factor: 2.153

4.  Psychometric testing of the consequences of an HIV disclosure instrument in Mandarin: a cross-sectional study of persons living with HIV in Hunan, China.

Authors:  Xueling Xiao; Junshi Zhao; Chulei Tang; Xianhong Li; Jane M Simoni; Honghong Wang; Kristopher P Fennie
Journal:  Patient Prefer Adherence       Date:  2018-08-17       Impact factor: 2.711

5.  HIV status disclosure by Nigerian men who have sex with men and transgender women living with HIV: a cross-sectional analysis at enrollment into an observational cohort.

Authors:  Abdulwasiu B Tiamiyu; John Lawlor; Fengming Hu; Afoke Kokogho; Manhattan E Charurat; Charles Ekeh; Merlin L Robb; Sylvia Adebajo; George Eluwa; Julie A Ake; Stefan D Baral; Rebecca G Nowak; Trevor A Crowell
Journal:  BMC Public Health       Date:  2020-08-26       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.